Lipoproteins as biosensors of endothelial oxidative status

Clinical Lipidology

Volumn 7, Issue 1, 2012, Pages 49-63

  Farkas Epperson, Monica ^a   Le, Ngoc Anh ^a  

^a ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

lipoprotein; oxidation hypothesis; oxidative susceptibility; oxidized LDL

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; ATORVASTATIN; CHYLOMICRON; EPITOPE; HIGH DENSITY LIPOPROTEIN; ISOPROSTANE; LIPOPROTEIN; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; OXIDATIVELY MODIFIED VERY LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PRAVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT CAPACITY; ARTERY ENDOTHELIUM; ARTERY WALL; ATHEROSCLEROSIS; BIOSENSOR; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; ENZYME ASSAY; FAMILIAL HYPERCHOLESTEROLEMIA; FOAM CELL; HEART PROTECTION; HUMAN; LIPID OXIDATION; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OXIDATION; OXIDATION KINETICS; OXIDATIVE STATUS; OXIDATIVE STRESS; OXIDATIVE SUSCEPTIBILITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW;

EID: 84856868772     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.72     Document Type: Review

References (145)

1. Watanabe T, Tanaka K, Yanai N. Essential familial hypercholesteremic xanthomatosis-an autopsy case with special reference to the pathogensis of cardiovascular lipidosis. Acta Pathol. Jpn 18, 319-331 (1968).
2. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46, 897-930 (1977).
3. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl Acad. Sci. USA 76, 333-337 (1979). (Pubitemid 9110191)
4. Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl Acad. Sci. USA 77, 2214-2218 (1980). (Pubitemid 10089629)
5. Basu SK, Goldstein JL, Anderson GW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fbroblasts. Proc. Natl Acad. Sci. USA 73, 3178-3182 (1976).
6. Hamberg M, Svensson J, Wakabayashi T, Samuelsson, B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Natl Acad. Sci. USA 71, 345-349 (1974).
7. Hammarstrom S, Falardeau P. Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets. Proc. Natl Acad. Sci. USA 74, 3691-3695 (1977). (Pubitemid 8189948)
8. Stossel TP, Mason RJ, Smith AL. Lipid peroxidation by human blood phagocytes. J. Clin. Invest. 54, 638-645 (1974).
9. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl Acad. Sci. USA 78, 6499-6503 (1981). (Pubitemid 12179740)
10. Hessler JR, Robertson AL Jr, Chisolm GM 3rd. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32, 213-229 (1979). (Pubitemid 9129780)
11. Bates SR, Wissler RW. Effect of hyperlipemic serum on cholesterol accumulation in monkey aortic medial cells. Biochim. Biophys. Acta 450, 78-88 (1976).
12. St Clair RW, Leight MA. Differential effects of isolated lipoproteins from normal and hypercholesterolemic rhesus monkeys on cholesterol esterifcation and accumulation in arterial smooth muscle cells in culture. Biochim. Biophys. Acta 530, 279-291 (1978). (Pubitemid 9000149)
13. Chen RM, Fischer-Dzoga K. Effect of hyperlipemic serum lipoproteins on the lipid accumulation and cholesterol fux of rabbit aortic medial cells. Atherosclerosis 28, 339-35 (1977).
14. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 2311-2316 (2010).
15. Wayner DD, Burton GW, Ingold KU, Locke S. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett. 187, 33-37 (1985). (Pubitemid 15250011)
16. Ghiselli A, Serafni M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic. Biol. Med. 29, 1106-1114 (2000).
17. Cao G, Alessio HM, Cutler RG. Oxygen-radical absorbance capacity assay for antioxidants. Free Radic. Biol. Med. 14, 303-311 (1993). (Pubitemid 23066371)
18. Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. J. Agric. Food Chem. 53, 1841-1856 (2005). (Pubitemid 40403051)
19. Huang D, Ou B, Hampsch-Woodhill M, Flanagan JA, Prior R. High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fuorescence reader in 96-well format. J. Agric. Food Chem. 50, 4437-4444 (2002). (Pubitemid 34823962)
20. Stocker R, Keaney JF Jr. Role of oxidative modifcations in atherosclerosis. Physiol. Rev. 84, 1381-1478 (2004).
21. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785-1792 (1991).
22. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin. Chim. Acta 411, 1875-1882 (2010).
23. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta 1128, 117-131 (1992).
24. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Potential role of oxidized lipids and lipoproteins in antioxidant defense. Free Rad. Res. 33, 197-215 (2000).
25. Rankin S, Parthasarathy S, Steinberg D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J. Lipid Res. 32, 449-456 (1991).
26. Klebanoff SJ. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77, 598-625 (2005). (Pubitemid 40628741)
27. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratifcation? Clin. Chem. 55, 1462-1470 (2009).
28. Hazen SL, Heinecke JW. 3-chlorotyrosine, a specifc marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99, 2075-2081 (1997). (Pubitemid 27203762)
29. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94, 437-444 (1994). (Pubitemid 24218123)
30. Vita JA, Brennan ML, Gokce N et al. Serum MPO levels independently predict endothelial dysfunction in humans. Circulation 110, 1134-1139 (2004). (Pubitemid 39319014)
31. Zhang R, Brennan ML, Fu X et al. Association between MPO levels and risk of CAD. JAMA 286, 2136-2142 (2001).
32. Ndrepepa G, Braun S, Schomig A, Kastrati, A. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin. Res. Cardiol. 100, 327-333 (2011).
33. Zhou T, Zhou S, Qi S, Shen X, Zeng G, Zhou H. The effect of atorvastatin on serum MPO and CRP levels in patients with acute coronary syndrome. Clin. Chim. Acta 368, 168-172 (2006). (Pubitemid 43776034)
34. Macphee CH, Nelson J, Zalewski A. Role of Lp-PLA2 in atherosclerosis and its potential as a therapeutic target. Curr. Opin. Pharmacol. 6, 154-161 (2006).
35. Corson M, Jones P, Davidson M. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am. J. Cardiol. 101(Suppl.), F41-F50 (2008).
36. Kiechl S, Willeit J, Mayr M et al. Oxidized phospholipids, Lp(a), LpPLA2 activity and 10-year cardiovascular outcomes. Prospective results from the Bruneck Study. Arterioscl. Thromb. Vasc. Biol. 27, 1788-1795 (2007). (Pubitemid 47207175)
37. Oei HHS, van der Meer IM, Hofman A et al. LpPLA2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation 111, 570-575 (2005). (Pubitemid 40216483)
38. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk In Communities (ARIC) study. Circulation 109, 837-842 (2004). (Pubitemid 38252734)
39. Schaefer EJ, McNamara JR, Asztalos BF et al. Effect of atorvastatin versus other statins on fasting and postprandial hsCRP and Lp-PLA2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol. 95, 1025-1032 (2005). (Pubitemid 40544302)
40. Mackness B, Prington P, McElduff P et al. Low PON1 activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107, 2775-2779 (2003). (Pubitemid 36705985)
41. Aviram M, Hardak E, Vava J et al. Human serum PON1 Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101, 2510-2517 (2000). (Pubitemid 30366256)
42. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol. Biol. 108, 101-106 (1998).
43. Yagi K. A simple fuorometric assay for lipoperoxide in blood plasma. Biochem. Med. 15, 212-216 (1976).
44. Bird RP, Hung SS, Hadley M, Draper HH. Determination of malonaldehyde in biological materials by high-pressure liquid chromatography. Anal. Biochem. 128, 240-244 (1983). (Pubitemid 13162722)
45. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and signifcance. Am. J. Clin. Nutr. 57, S715-S725 (1993).
46. Draper HH, Squires EJ, Mahmoodi H, Wu J, Agarwal S, Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic. Biol. Med. 15, 353-363 (1993). (Pubitemid 23283552)
47. Chirico S. High-performance liquid chromatography-based thiobarbituric acid tests. Methods Enzymol. 233, 314-318 (1994).
48. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 15, 316-328 (2005). (Pubitemid 41190990)
49. Walter MF, Jacobs RF, Jeffers B et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal ana lysis of the PREVENT study. J. Am. Coll. Cardiol. 44, 1996-2002 (2004). (Pubitemid 39473284)
50. Morrow J. Quantifcation of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscl. Thromb. Vasc. Biol. 25, 279-286 (2005). (Pubitemid 40189146)
51. Practico D, Iuliano L, Mauriello A et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 103, 421-427 (1997).
52. Practico D, Tangirala RK, Rader DJ, Rokach J, Fitzgerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-defcient mice. Nat. Med. 4, 1189-1192 (1998). (Pubitemid 28468835)
53. Tsimikas S. Measures of oxidative stress. Clin. Lab. Med. 26, 571-590 (2006). (Pubitemid 44308368)
54. Ky B, Burke A, Tsimikas S et al. The infuence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol. 51, 1653-1662 (2008). (Pubitemid 351626406)
55. Shao B, Heinecke JW. Using tandem mass spectrometry to quantify site-specifc chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 440, 33-63 (2008).
56. Shao B, Pennathur S, Pagani I et al. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol effux by the ABCA1 pathway. J. Biol. Chem. 285, 18473-18484 (2010).
57. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinfammatory properties of HDL. J. Clin. Invest. 117, 746-756 (2007). (Pubitemid 46348533)
58. Rosenfeld ME, Palinski W, Yla-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specifc lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 10, 336-349 (1990). (Pubitemid 20178662)
59. Palinski W, Horkko S, Miller E et al. Cloning of MAb to epitopes of oxidized lipoproteins from apoE-defcient mice. Demonstration of epitopes of oxidized LDL in human plasma. J. Clin. Invest. 98, 800-814 (1996). (Pubitemid 26349186)
60. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. LDL undergoes oxidative modifcation in vivo. Proc. Natl Acad. Sci. USA 86, 1372-1376 (1989). (Pubitemid 19061548)
61. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-defcient rabbits with homologous malondialdehyde-modifed LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA 92, 821-825 (1995).
62. Virella G, Lopes-Virella MF. Lipoprotein autoantibodies: measurement and signifcance. Clin. Diagn. Lab. Immunol. 10, 499-505 (2003).
63. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL-receptor defcient mice with increased atherosclerosis. Arterioscl. Thromb. Vasc. Biol. 15, 1569-1576 (1995).
64. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against LDL and progression of carotid atherosclerosis. Lancet 339, 883-887 (1992).
65. Puurunen M, Manttari M, Manninen V et al. Antibody against oxidized LDL predicting myocardial infarction. Arch. Intern. Med. 154, 2605-2609 (1994). (Pubitemid 24362412)
66. Bui MN, Sack MN, Moutsatsos G et al. Autoantibody titers to oxLDL in patients with coronary atherosclerosis. Am. Heart J. 131, 663-667 (1996). (Pubitemid 26116341)
67. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 102, 2576-2581 (2000).
68. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Yla-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20, 204-209 (2000). (Pubitemid 30048365)
69. van de Vijver LPL, Steyger R, van Poppel G et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122, 245-253 (1996). (Pubitemid 26156726)
70. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to oxLDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A2. Arterioscl. Thromb. Vasc. Biol. 21, 169-174 (2001).
71. Uusitupa MI, Niskanen L, Luoma J et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16, 1236-1242 (1996). (Pubitemid 26339710)
72. Le NA, Li X, Kyung S, Brown W V. Evidence for the in vivo generation of oxidatively modifed epitopes in patients with documented CAD. Metabolism 49, 1271-1277 (2000).
73. Gradek Q, Harris M, Yahia N, Davis W, Le NA, Brown W. Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modifed LDL in patients with vascular disease. Am. J. Cardiol. 93, 881-885 (2004). (Pubitemid 38429601)
74. Itabe H, Yamamoto H, Imanaka T et al. Sensitive detection of oxidatively modifed low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37, 45-53 (1996). (Pubitemid 26052618)
75. Holvoet P, Donck J, Landeloos M et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb. Haemost. 76, 663-669 (1996). (Pubitemid 26388165)
76. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modifed LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am. J. Pathol. 135, 815-825 (1989). (Pubitemid 20009491)
77. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-defcient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specifc epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14, 605-616 (1994).
78. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am. J. Cardiol. 98, 9P-17P (2006).
79. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr. Opin. Lipidol. 20, 363-369 (2009).
80. Briley-Saebo KC, Cho YS, Tsimikas S. Imaging of oxidation-specifc epitopes in atherosclerosis and macrophage-rich vulnerable plaques. Curr. Cardiovasc. Imaging Rep. 4, 4-16 (2011).
81. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and infammatory cytokines (AIR Study). Arterioscler. Thromb. Vasc. Biol. 22, 1162-1167 (2002). (Pubitemid 34764868)
82. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with increased levels of cell-adhesion molecules in clinically healthy 58-year old men (AIR study). Med. Sci. Monit. 8, CR148-CR152 (2002). (Pubitemid 34263043)
83. Hulthe J, Fagerberg B. Circulating oxLDL is assocaited with increased levels of cell-adhesion molecules in clinically healthy 58-yr old men (AIR study). Med. Sci. Monit. 8, CR148-CR152 (2002). (Pubitemid 34263043)
84. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome LDL size in clinically healthy 58-year-old men (AIR study). J. Intern. Med. 252, 440-447 (2002). (Pubitemid 36706575)
85. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J. Intern. Med. 256, 413-420 (2004). (Pubitemid 39434378)
86. Holvoet P, Kritchevsky SB, Tracy RP et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53, 1068-1073 (2004). (Pubitemid 38436620)
87. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 194, 245-252 (2007). (Pubitemid 47464304)
88. Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353, 46-57 (2005) (Pubitemid 41007806)
89. Le NA. Oxidized lipids and lipoproteins: Indices of risk or targets for management. Clin. Lipidol. 4, 41-54 (2009).
90. Tsimikas S, Aikawa M, Miller FJ et al Increased plasma oxidized phospholipid:ApoB-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid lowering. Arterioscl. Thromb. Vasc. Biol. 27, 175-181 (2007). (Pubitemid 46360396)
91. Tsimikas S, Witztum JL, Miller ER et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110, 1406-1412 (2004). (Pubitemid 39238018)
92. Rodenburg J, Vissers MN, Wiegman A et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J. Am. Coll. Cardiol. 47, 1803-1810 (2006).
93. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specifc monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler. Thromb. Vasc. Biol. 20, 689-697 (2000). (Pubitemid 30151682)
94. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004). (Pubitemid 38541684)
95. Nissen SE. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am. J. Med. 118(Suppl. 12A), 22-27 (2005).
96. Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J. Biol. Chem. 255, 1839-1848 (1980). (Pubitemid 10114813)
97. Bersot TP, Innerarity TL, Mahley RW, Havel RJ. Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. J. Clin. Invest. 72, 1024-1033 (1983). (Pubitemid 14212620)
98. Kawakami A, Tani M, Chiba T et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 25, 424-429 (2005). (Pubitemid 40189168)
99. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins. Comparison of very low density lipoprotein from subjects with type III, IV, and V hyperlipoproteinemias. Arterioscler. Thromb. 11, 221-233 (1991).
100. Doi H, Kugiyama K, Oka H et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102, 670-676 (2000). (Pubitemid 30640668)
101. Park SY, Lee JH, Kim YK et al. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J. Pharmacol. Exp. Ther. 312, 1241-1248 (2005).
102. Nakajima K, Nakano T, Tanaka A. The oxidative modifcation hypothesis of atherosclerosis: the comparison of atherogenic effects of oxidaized LDL and remnant lipoproteins in plasma. Clin. Chim. Acta 367, 36-47 (2006).
103. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc. Res. 59, 169-180 (2003). (Pubitemid 36776383)
104. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 9, 726-735 (1995).
105. Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff M W. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms. J. Lipid Res. 34, 703-717 (1993). (Pubitemid 23152919)
106. Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler. Thromb. Vasc. Biol. 17, 1707-1715 (1997). (Pubitemid 27423991)
107. Jong MC, Hendriks WL, van Vark LC, Dahlmans VE, Groener JE, Havekes LM. Oxidized VLDL induces less triglyceride accumulation in J774 macrophages than native VLDL due to an impaired extracellular lipolysis. Arterioscler. Thromb. Vasc. Biol. 20, 144-151 (2000). (Pubitemid 30048357)
108. Guha M, Gursky O. Effects of oxidation on structural stability and remodeling of human very low density lipoprotein. Biochemistry 49, 9584-9593 (2010).
109. Wang GP, Deng ZD, Ni J, Qu ZL. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis 133, 31-36 (1997). (Pubitemid 27322114)
110. Mabile L, Salvayre R, Bonnafe MJ, Negre-Salvayre A. Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Free Radic. Biol. Med. 19, 599-607 (1995).
111. Mabile L, Salvayre R, Bonnafe MJ, Negre-Salvayre A. Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Free Radic. Biol. Med. 19, 599-607 (1995).
112. Liu BW, Jiang Y, Fu MD, Liu Y, Fan P. Oxidative modifcation of lipoproteins in hypertriglyceridemic patients and hypercholesterolemic rabbits in vivo. Mol. Cell. Biochem. 207, 131-135 (2000). (Pubitemid 30399380)
113. Jiang X, Bruce C, Mar J et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces HDL levels. J. Clin. Invest. 103, 907-914 (1999). (Pubitemid 29152637)
114. Karkkainen M, Oka T, Olkkonen V et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J. Biol. Chem. 277, 15413-15418 (2002). (Pubitemid 34967804)
115. Hendrickson A, McKinstry LA, Lewis JK et al. Ex vivo measures of LDL oxidative susceptibility predict carotid artery disease. Atherosclerosis 179, 147-153 (2005). (Pubitemid 40249797)
116. Ryglewicz D, Rodo M, Roszczynko M et al. Dynamics of LDL oxidation in ischemic stroke patients. Acta Neurol. Scand. 105, 185-188 (2002). (Pubitemid 34258959)
117. McEneny J, Kane MJO, Moles KW et al. VLDL subfractions in type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 43, 485-493 (2000). (Pubitemid 30237958)
118. McEneny J, Loughrey CM, McNamee PT, Trimble ER, Young IS. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 129, 215-220 (1997). (Pubitemid 27135323)
119. Nielsen NS, Pedersen A, Sandstrom B, Marckmann P, Hoy CE. Different effects of diets rich in olive oil, rapeseed oil and sunfower-seed oil on postprandial lipid and lipoproteins concentrations and on lipoprotein oxidation susceptibility. Br. J. Nutr. 87, 489-499 (2002). (Pubitemid 34575570)
120. Kaikkonen J, Porkkala-Sarataho E, Tuomainen TP et al. Exhaustive exercise increases plasma/serum total oxidation resistance in moderately trained men and women, whereas their VLDL+LDL lipoprotein fraction is more susceptible to oxidation. Scand. J. Clin. Lab. Invest. 62, 599-608 (2002). (Pubitemid 36071958)
121. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL, Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modifcation: implications for dietary prevention of atherosclerosis. Proc. Natl Acad. Sci. USA 87, 3894-3898 (1990).
122. Reaven P, Parthasarathy S, Grasse BJ et al. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modifcation in humans. Am. J. Clin. Nutr. 54, 701-706 (1991). (Pubitemid 21898990)
123. Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modifcation in mildly hypercholesterolemic subjects. J. Clin. Invest. 91, 668-676 (1993). (Pubitemid 23064153)
124. Parks EJ, German JB, Davis PA et al. Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis treatment program. Am. J. Clin. Nutr. 68, 778-785 (1998). (Pubitemid 28471060)
125. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. HDL as a protective factor against CHD. Am. J. Med. 62, 707-714 (1977).
126. Wilson PW, Abbott RD, Castelli W P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8, 737-741 (1988). (Pubitemid 19005358)
127. Gordon DJ, Probstfeld JL, Garrison RJ et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15 (1989). (Pubitemid 19043669)
128. Shah PK, Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 85, 1279-1285 (1992).
129. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85, 37-45 (1992).
130. Manttari M, Huttunen JK, Koskinen P et al. Lipoproteins and coronary heart disease in the Helsinki Heart Study. Eur. Heart J. 11(Suppl. H), 26-31 (1990).
131. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208, 3-9 (2010).
132. Fazio S, Linton MF. Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma. J. Clin. Endocrinol. Metab. 94, 1081-1083 (2009).
133. Frikke-Schmidt R, Nordestgaard BG, Stene MC et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299, 2524-2532 (2008). (Pubitemid 351787208)
134. Roma P, Gregg RE, Meng MS et al. In vivo metabolism of a mutant form of apolipoprotein A-I, Apo A-IMilano, associated with familial hypoalphalipoproteinemia. J. Clin. Invest. 91, 1445-1452 (1993). (Pubitemid 23127345)
135. Johannsen TH, Kamstrup PR, Andersen RV et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J. Clin. Endocrinol. Metab. 94, 1264-1273 (2009).
136. Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923 (1996). (Pubitemid 26197108)
137. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8, 222-232 (2011).
138. Navab M, Hama SY, Anantharamaiah GM et al. Normal HDL inhibits 3 steps in the formation of mildly oxidized LDL: steps 2 and 3. J. Lipid Res. 41, 1495-1508 (2000).
139. Van Lenten BJ, Hama SY, de Beer FC et al. Anti-infammatory HDL becomes pro-infammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767 (1995).
140. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-infammatory properties during acute infuenza a infection. Circulation 103, 2283-2288 (2001). (Pubitemid 32433719)
141. Ansell BJ, Navab M, Hama S et al. Infammatory/antiinfammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108, 2751-2756 (2003). (Pubitemid 37498976)
142. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol. 30, 151-155 (2010).
143. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate effux of cholesterol from foam cells after oxidative modifcation. Proc. Natl Acad. Sci. USA 88, 6457-6461 (1991). (Pubitemid 21914965)
144. Salmon S, Maziere C, Auclair M, Theron L, Santus R, Maziere JC. Malondialdehyde modifcation and copper-induced autooxidation of high-density lipoprotein decrease cholesterol effux from human cultured fbroblasts. Biochim. Biophys. Acta 1125(2), 230-235 (1992).
145. McPherson P, Young I, McKibben B, McEneny J. HDL subfractions: isolation, composition, and their duplicitous role in oxidation. J. Lipid Res. 48, 86-95 (2007). (Pubitemid 46052900)